HIV-1 invades CNS in the early course of infection, which can lead to the cascade of neuroinflammation. NADPH oxidases (NOXs) are the major producers of reactive oxygen species (ROS), which play important roles during pathogenic insults. The molecular mechanism of ROS generation via microRNA-mediated pathway in human microglial cells in response to HIV-1 Tat protein has been demonstrated in this study. Over-expression and knockdown of microRNAs, luciferase reporter assay, and site-directed mutagenesis are main molecular techniques used in this study. A significant reduction in miR-17 levels and increased NOX2, NOX4 expression levels along with ROS production were observed in human microglial cells upon HIV-1 Tat C exposure. The validation of NOX2 and NOX4 as direct targets of miR-17 was done by luciferase reporter assay. The over-expression and knockdown of miR-17 in human microglial cells showed the direct role of miR-17 in regulation of NOX2, NOX4 expression and intracellular ROS generation. We demonstrated the regulatory role of cellular miR-17 in ROS generation through over-expression and knockdown of miR-17 in human microglial cells exposed to HIV-1 Tat C protein. (Tat) is a regulatory protein and among the early HIV proteins to be produced after infection. HIV Tat protein has been reported in serum of HIV-1-infected patients (Westendorp et al. 1995; Goldstein 1996; Xiao et al. 2000) , where its concentration can reach up to 300-500 ng/mL (Poggi et al. 2004) . HIV Tat protein is released from HIV-1-infected cells (Ensoli et al. 1990) 
Human immunodeficiency virus (HIV) belongs to genus lentivirus and Retroviridae family, whose characteristic tendency is to cause subacute neurologic disease in host (Mayer and Schmidtmayerova 1997) . Approximately 70% of HIV-infected patients develop HIV-associated neurological disorders during different stages of disease development (Clark and Vinters 1987) . HIV enters in brain through infected monocytes/macrophages (Trojan horse mechanism) by compromising blood-brain barrier permeability during early course of acute infection (Koenig et al. 1986; Hazleton et al. 2010; Dohgu et al. 2011) . Neurons are not directly infected by HIV, although other cells like astrocytes, microglia and perivascular macrophages get productively infected and serve as HIV reservoir. HIV has been isolated from CNS of AIDS patients with or without neuropsychiatric sequelae (Mayer and Schmidtmayerova 1997) . HIV affects uninfected cells in a bystander fashion through the extracellularly secreted HIV proteins like Tat (Eugenin and Berman 2007; Li et al. 2009b) . HIV-1 transactivator of transcription (Tat) is a regulatory protein and among the early HIV proteins to be produced after infection. HIV Tat protein has been reported in serum of HIV-1-infected patients (Westendorp et al. 1995; Goldstein 1996; Xiao et al. 2000) , where its concentration can reach up to 300-500 ng/mL (Poggi et al. 2004) . HIV Tat protein is released from HIV-1-infected cells (Ensoli et al. 1990 ) and can be efficiently taken up by neighboring cells, where it can alter the host gene expression including small RNAs in a bystander manner (Li et al. 2009b) .
MicroRNAs are 19-23 nucleotides, non-coding, small RNAs which bind to complementary region, within 3 0 UTR (untranslated regions) of target genes through its seed region and regulate the expression of target genes (Lee et al. 2003; Bartel 2004; Singh 2007) . HIV 1 Tat protein is extensively reported to modulate the expression of microRNAs (Eletto et al. 2008) . We previously reported microRNA-mediated regulation of various genes (Mishra et al. 2012; Mishra and Singh 2013) in human microglial cells and brain microvascular endothelial cells in response to HIV-1 Tat C protein.
Microglial cells are brain resident macrophages, whose state of activation decides its role in protection or inflammation. Three phenotypic states of microglia are known; first, the ramified state, which is a resting state; second, the activated non-phagocytic state (found in areas involved in CNS inflammation), and third is the reactive, phagocytic state (found in areas of trauma or cell injury) (Frei et al. 1987; Suzumura et al. 1987; Williams et al. 1992; Panek and Benveniste 1995; Walker et al. 1995) . Upon activation, microglial cells undergo morphological changes and alterations in patterns of gene expression profiles (Tambuyzer et al. 2009 ). Microglial cells have the ability to produce reactive oxygen species (ROS) through NADPH oxidases (NOX). Seven isoforms of NADPH oxidases (NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1, and DUOX2) have been reported to play roles in ROS production. Out of these, NOX2 and NOX4 are well studied for their predominant role in ROS generation. NOX2 and NOX4 are known to be expressed in microglial cells (Lavigne et al. 2001; Vilhardt et al. 2002; Sorce and Krause 2009) . Activation of NOX2 (also known as gp91 phox ) takes place via interaction of various NOX subunits. Its interaction with p22 phox and association of cytosolic factors p47 phox , p67
phox to NOX2/ p22 phox are required for its activation (Groemping and Rittinger 2005) . NOX4 is p22 phox -dependent enzyme and does not need cytosolic subunits for its activation (Martyn et al. 2006) . ROS is produced mostly by NOX enzymes in microglial cells (Babior 2004) , as a defense mechanism. However, the excessive generation of ROS through NOX genes upon microglial activation could lead to neurotoxicity.
ROS results in elevated cytokine and chemokine production by microglial cells, thus indicating activation of microglial cells (Qin et al. 2004; Block and Hong 2005; Yang et al. 2007) . Activated microglia are known to secrete various pro-inflammatory cytokines, which play important roles in neuroinflammation (Jovanovic 2012; Baby et al. 2014) . ROS is known to aggravate HIV-associated diseases among AIDS patients (Salmen and Berrueta 2012) . ROS such as H 2 O 2 can enter into cells by crossing biological membrane through aquaporin channels (Bienert and Chaumont 2014 
À.
HIV proteins such as Vpr and Tat have been reported to perturb the miRNA expression in human microglial and neuronal cells Sun and Rossi 2011; Klase et al. 2012) . In this study, we demonstrated the regulation of NOX2 and NOX4 through miR-17. The expression of miR-17 was attenuated by HIV-1 Tat C, which led to increased expression of NOX2, NOX4, and thereby ROS generation in human microglial cells.
Materials and methods

Cell culture
Human microglia clone 3 cell lines (HMC3) (Janabi et al. 1995) were obtained from Dr Karl-Heinz Krause, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Switzerland as a kind gift. HMC3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, #12100-046; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (#16000-044; Invitrogen), 100 U penicillin, and 100 lg/mL streptomycin (#10378016; Invitrogen). CEM-GFP cells (reporter T cell line) (NIH-AIDS Reagent Program, Germantown, MD, USA) were cultured in RPMI 1640 (23400-021; Gibco-BRL, Gaithersburg, MD, USA) with 10% fetal bovine serum, 100 U penicillin, and 100 lg/mL streptomycin. CEM-GFP cells were used for transactivation assay of HIV-1 Tat protein. HeLa cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U penicillin, and 100 lg/mL streptomycin for Luciferase assay. HMC3 cells were cultured in white bottom 96-well plates (#3917; Corning Inc, New York, NY, USA) for ROS detection by fluorimetry. HMC3 cells were cultured in 12-well culture plates for ROS imaging experiments. All the cultures were incubated in humidified atmosphere (5% CO 2 ) at 37°C.
Expression and purification of HIV-1 Tat C protein HIV-1 Tat C gene was amplified from HIV-1-infected cells and was cloned in pET-21b bacterial expression vector with His-tag attached to Tat at C-terminal. It was transformed in BL21 (DE3) cells, which were cultured in Luria Broth (LB) and induced by isopropyl-b-Dthio-galactosidase (IPTG) for 3 h for protein expression. Bacterial cells were pelleted and resuspended in 20 mL of lysis buffer (50 mM phosphate buffer pH 7.9, 0.4 mM EDTA pH 8, 300 mM KCl, 10 mM imidazole, 0.2 mM phenylmethanesulphonyl fluoride, 1 mM dithiothreitol, 0.1% tritonX-100). Cells were lysed by sonication and lysates were further used for purification. His-tagged recombinant HIV-1 Tat C protein was purified by affinity chromatography using nickel-nitrilotriacetic acid (Ni-NTA columns). Lysate was incubated with Ni-NTA column overnight at 4°C. Protein was eluted in elution buffer (Phosphate buffer pH 8, 300 mM imidazole) and was used for removal of imidazole in centrifugal concentrator (Amicon MWCO 3 kDa, UFC900396; Millipore Corporation, Bedford, MA, USA). Imidazole removal buffer (30 mM phosphate buffer, 70 mM KCl, 1 mM dithiothreitol) was used for concentrating the protein and aliquots were stored at À80°C for further experimental use. The expression and purification steps of this Tat 1-101 (11.51 kDa) were followed as per our standardized proto-cols, protein was tested for its endotoxin levels, checked for its functional activity, and confirmed by western blotting as described in our previous reports (Mishra et al. 2012; Mishra and Singh 2013 MicroRNA over-expression HMC3 cells were seeded and grown till 40-50% confluency. Transfection mixtures were prepared in low serum Opti-MEM media (#11058-021; Ambion, Foster City, CA, USA) and transfection was carried out using antibiotic-free media. Over-expression of miR-17 was done by transfecting 100pM miR-17 oligos (BioServe, Mallapur, Hyderabad, India) (sequence mentioned in Table 1 ) with Lipofectamine 2000 (#11668-019; Invitrogen). 100pM scramble miR-17 (sequence given in Table 1 ) was transfected in HMC3 cells as negative control. Over-expression of miR-101 was performed by transfecting 100pM of miR-101 oligos (sequence mentioned in Table 1 ) as non-target control. After 48 h, the over-expression of miRNAs was confirmed by qPCR using respective TaqMan probes. The expression levels of NOX2 and NOX4 were checked by western blot analysis.
MicroRNA inhibition
Cellular miR-17 was inhibited by transfecting HMC3 cells with 100pM of anti-miR-17 (MH12412; Ambion) and Cy3-labeled negative control (anti-miR) with Lipofectamine 2000 for 48 h. Transfection efficiency was determined by visualizing Cy3-labeled anti-miR fluorescence in transfected control HMC3 cells. The levels of expressions of NOX2 and NOX4 protein expressions were analyzed by western blot analysis in anti-miR-17-transfected cells.
Site-directed mutagenesis
As per the bioinformatic analysis, three sites (7-mer, 6-mer, and 5-mer) of miR-17 binding in 3 0 UTR of NOX2 and three sites (all 7-mer) in NOX4 3 0 UTR were predicted. Complementary binding sequences GCACTTT were deleted from sites 195-201 (MUT1), GCACT from sites 1803-1808 (MUT2), and GCACTT from sites 2316-2322 (MUT3) in NOX2 3 0 UTR. However, the complementary binding sequences GCACTTT were deleted from sites 988-994 (MUT1), 1191-1197 (MUT2), and 1369-1375 (MUT3) in NOX4 3 0 UTR, The mutants were created by site-directed mutagenesis using primers listed in Table 2 . PCR was carried out using 50 ng plasmid template, 0.3 lM primers in Phusion High-Fidelity master mix buffer (#M0531; New England Biolabs, Ipswich, MA, USA) at was constructed using these mutated fragments (MUT1, MUT2, and MUT3) through recombination PCR, was further cloned in psiCHECK-2 vector. These mutants were then used as set of negative controls for Luciferase assay.
Luciferase reporter assay
Luciferase reporter clones of intact sequences WT NOX2 3 0 UTR (cloned in psiCHECK-2 Vector, #C8021; Promega, Madison, WI, USA), WT NOX4 3 0 UTR (#HmiT054569-MT01; GeneCopeia), mutant-NOX2 3 0 UTR clone, and mutant-NOX4 3 0 UTR clones were cotransfected individually with miR-17 oligos in HeLa cells.
Luciferase assay was performed after 24 h of transfection using luciferase assay kit (#E4030; Promega). b-galactosidase assay has been performed (#E2000; Promega) for normalization, according to the manufacturer's protocol. Samples were read using multimode plate reader (EnSpire, PerkinElmer).
Intracellular ROS detection HMC3 cells were seeded in 96-well bottom plates and were allowed to adhere overnight. Cells were treated with 1 lg/mL concentration of HIV-1 Tat C protein upon confluency, for different time points. Cells were washed and stained with 5 lM DCFDA (#D6883-250 mg; Sigma-Aldrich) for 15 min at 37°C. Cells fluorescence was measured at 480 nm/535 nm on multimode plate reader (EnSpire, PerkinElmer) at each time point. Cells were stained and incubated with same concentration of DCFDA, washed with phosphatebuffered saline, and images were captured by Zeiss Axiocam MRC fluorescent microscope (Carl Zeiss, Gottingen, Germany) for imaging experiment of intracellularly generated ROS. ROS measurement was done in cells after over-expressing miR-17 and inhibiting miR-17. Cells were seeded in 96-well plates and ROS levels were checked after 12 h of transfections. In the experiments of over-expression followed by HIV-1 Tat C treatment and HIV-1 Tat C treatment alone, cells were treated with HIV-1 Tat C protein after 6 h of seeding of cells in 96-well plates. The HMC3 cells exposed to HIV-1 Tat C protein for 24 h were used for DCFDA staining and fluorescence measurement.
Expression of cytokines and evaluation of miR-17 expression levels in HMC3 cells exposed to different stimuli Cytokine levels in cells over-expressing miR-17 and cells in which miR-17 was inhibited were determined through quantitative PCR. RNA was isolated (as mentioned above) from cells transfected with scramble miR-17, miR-17 oligos, Cy3, and anti-miR-17. Two micrograms of RNA was converted into cDNA using Superscript II reverse transcriptase system (#11904-018; Invitrogen) according to the manufacturer's protocol. Two hundred nanograms of cDNA was then used to perform quantitative/RT-PCR using SYBR Green Supermix (#4367659; Applied Biosystems). Expression levels of TNF-a, IL-1b, and IL-6 were determined using cytokine-specific primers (Table 2) and Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) was used as internal control. To demonstrate the specificity of miR-17 expression in response to HIV-1 Tat C protein, we exposed HMC3 cells with different cell stimulants such as HIV-1 Tat B (recombinant Tat B protein), lipopolysaccharide (LPS, Sigma-Aldrich), and bovine serum albumin (BSA, #NEB 
Results
HIV-1 Tat C treatment decreases the expression level of miR-17 in HMC3 cells
We studied the changes in expression level of miR-17 in HMC3 cells exposed to HIV-1 Tat C protein at various time points. Real-time quantitative (qPCR) analysis with TaqMan microRNA assay specific to miR-17 showed that mature miR-17 levels significantly decreased upon HIV-1 Tat C exposure at 6, 12, and 24 h (Fig. 1b) compared to 0-h control. The miR-17 levels were significantly decreased at 6 h (34% decrease), 12 h (24% decrease), and at 24 h (54% decrease) (p ≤ 0.05), compared to untreated control cells.
HIV-1 Tat C treatment induces expression level of NOX2 and NOX4 in HMC3 cells
To study the effect of HIV-1 Tat C on NOX2 and NOX4 expression in HMC3 cells, we determined the levels of their expressions at 0, 6, 12, and 24 h after HIV-1 Tat C treatment (Fig. 1a) . HIV-1 Tat C exposure for the above-mentioned time points resulted into increased expression of NOX2 and NOX4. A significant increase in NOX2 expression level was observed within each time-point interval, compared to controls, (Fig. 1c) . NOX2 expression was increased by twofolds at 6 h (**p ≤ 0.01), 3.2 folds at 12 h (***p ≤ 0.001), and maximum of fivefolds at 24 h (***p ≤ 0.001), as compared to controls. Steady increase in NOX4 expression was noted with 1.5 folds higher at 6 h, 1.75 folds at 12 h (*p ≤ 0.05), and highest of 2.6 folds at 24 h (*p ≤ 0.05), as compared to controls. Significant changes between the time intervals of 6-24 h (##p ≤ 0.01) were also observed (Fig. 1d) .
miR-17 directly binds to 3 0 UTRs of NOX2 and NOX4 miRNAs contain 2-8 nt seed region, having complementarity with their 3 0 UTR of target mRNAs. MicroRNAs regulate the expression levels of target genes post-transcriptionally, either by repression of translation or by degrading target mRNA. We detected reduced levels of miR-17 on HIV-1 Tat C treatment at 6, 12, and 24 h time points (Fig. 1a) . Bioinformatics tools were used to analyze the binding of miR-17 with NOX2 and NOX4. 3 0 UTR of NOX2 and NOX4 showed strong and multiple binding sites for miR-17. To confirm the miRNA binding, we performed luciferase assay, where HeLa cells were transfected with reporter construct of WT NOX2, NOX4 and mutant NOX2, NOX4 3 0 UTR. Only the WT 3 0 UTR constructs and miR-17 oligos cotransfected cells showed reduced luciferase activity by 50% (p < 0.05) for NOX2 ( Fig. 2) and by 38% (p < 0.005) for NOX4 (Fig. 3) . To further confirm, the mutants of NOX2 and NOX4 were cotransfected with miR-17 oligos, which did not result into significant decrease in luciferase activity. miR-101 was also cotransfected with 3 0 UTR reporter constructs of NOX2 and NOX4 and no change was observed in luciferase activity, which indicated the specificity of binding of miR-17 with the 3 0 UTRs of their target genes NOX2 and NOX4 (Figs 2 and 3) .
Over-expression of miR-17 suppresses the expression of NOX2 and NOX4 We confirmed that NOX2 and NOX4 had strong binding sites for miR-17 by luciferase reporter assay. The expression levels of NOX2 and NOX4 were analyzed in miR-17 overexpressed HMC3 cells and by western blotting analysis (Fig. 4b) . Over-expression was confirmed by real-time PCR for miR-17-specific Taqman primer as probe (Fig. 4a) . miR-17 was found to be over-expressed by 526.6 folds, compared to untransfected control (*p ≤ 0.05) and scramble miR-17-transfected cells (#p ≤ 0.05). miR-101 was also overexpressed as 21.6 folds compared to control (**p ≤ 0.01), to study the effect of non-specific miRNA (Fig. 4a) . Increased levels of miR-17 in cells significantly downregulated the expression of NOX2 by 65% as compared to control (p ≤ 0.005) (Fig. 4c) . NOX2 was significantly downregulated in miR-17 over-expressing cells, compared to scramble miR-17 and non-specific miR-101 controls (p ≤ 0.01, p ≤ 0.01, respectively). The over-expression of miR-17 resulted into the significant decrease (~70%) in NOX4 expression, compared to control (p ≤ 0.005) (Fig. 4d) . NOX-4 was also significantly down-regulated compared to scramble miR-17 (p ≤ 0.005) and non-specific miR-101 (p ≤ 0.05).
Inhibition of miR-17 enhances the expression of NOX2 and NOX4
The HMC3 cells were transfected with anti-miR-17 to inhibit the cellular mature miR-17 and to study the knockdown effect of miR-17 on the expression levels of NOX2 and NOX4. Inhibition of miR-17 was confirmed by qPCR using miR-17 specific TaqMan probes (Fig. 5a ). Anti-miR-17-transfected HMC3 cells showed the significant inhibition of mature miR-17 by 87% as compared to control (**p ≤ 0.01) and Cy3 control (#p ≤ 0.05). Expression levels of NOX2 and NOX4 were checked by western blotting (Fig. 5b) . Increase in NOX2 expression [2.9 folds (*p ≤ 0.05)] (Fig. 5c ) and NOX4 [2.5 folds (**p ≤ 0.01)] was observed in anti-miR-17-transfected HMC3 cells, as compared to controls (Fig. 5d) . These changes were statistically significant compared to Cy3 controls (#p ≤ 0.05, #p ≤ 0.05, respectively). HIV-1 Tat C exposure showed similar reduction in miR-17 levels and reflected similar trends in the expression levels of . Densitometry analysis of western blots for NOX2 and NOX4 expression. Significant decrease in NOX2 and NOX4 levels was found in comparison to all controls, untransfected, scramble-miR-17 and non-specific miR-101 (*p ≤ 0.05, **p ≤ 0.01,***p ≤ 0.001) and no change was observed when scramble miR-17 and non-specific miR-101 were transfected. All experiments were performed in sets of three and data are presented as mean AE SE of three independent experiments. NOX2 and NOX4. NOX2 expression increased by fourfolds, whereas NOX4 expression was increased by 1.7 folds (*p ≤ 0.05, *p ≤ 0.05, respectively).
Over-expression of miR-17 decreases intracellular ROS production in HMC3 cells
Whether miR-17 directly has any effect on intracellular ROS production; ROS levels were studied by over-expressing miR-17 in HMC3 cells. The abundance of miR-17 in HMC3 cells could reduce ROS levels close to normal. Scramble miR-17 and non-specific miR-101 were used as controls and did not show any significant change in ROS levels (Fig. 6c) . Any significant increase was not observed in the levels of ROS in miR-17 over-expressing HMC3 cells exposed to HIV-1 Tat C, as observed in HMC3 cells exposed to HIV-1 Tat C protein alone (fold change 1.22 folds, p ≤ 0.01) (Fig. 6c) . This demonstrated that miR-17 regulates the intracellular ROS levels through direct targeting of NOX2 and NOX4.
HIV-1 Tat C induces intracellular ROS level NADPH oxidases are the major sources of ROS, generation especially in glial cells. As miR-17 was down-regulated upon HIV-1 Tat C treatment and NOX2 and NOX4 were elevated, we checked intracellular ROS production at 0, 6, 12, and 24 h. ROS levels were checked by fluorimetry in DCFDAstained HMC3 cells. Significant increase in ROS generation was observed at each time point with highest of 1.16 folds at 24 h (p ≤ 0.01) (Fig. 6a) . This was also confirmed by imaging analysis of HIV-1 Tat C exposed HMC3 cells at 24 h. Image analysis showed the increased intensity of DCFDA-stained cells and enhanced production of ROS as compared to controls (Fig. 6b) . Zero-hour control showed no ROS production (Fig. 6bi) . Control cells were kept in incomplete DMEM for 24 h and stained by DCFDA. There was no significant ROS production in control cells (Fig. 6bii) ; however, the HMC3 cells exposed to HIV-1 Tat C protein for 24 h have shown significant ROS production (Fig. 6biii) .
Anti-miR-17 elevates intracellular ROS levels miR-17 regulates the expression of NOX2 and NOX4 by binding to their 3 0 UTRs. Inhibition of miR-17 resulted in enhanced expression of NOX2 and NOX4. To study if reduction in miR-17 levels affects intracellular ROS production, the ROS levels were measured in cells transfected with anti-miR-17 (miR-17 inhibitor). ROS production was increased by 1.9 folds (p ≤ 0.01) in HMC3 cells as compared to controls upon inhibiting miR-17. Cy3 was used as negative control and showed no change in ROS levels (Fig. 6c) . This trend corroborated with increase of ROS found in HIV-1 Tat Ctreated cells. We demonstrated that miR-17 directly regulates the expression of NOX2 and NOX4 and thus its downstream function in terms of intracellular ROS production.
Increased ROS leads to microglial activation and HIV-1 Tat C specifically modulates miR-17 levels in HMC3 cells Reduced levels of miR-17 resulted in increased expression of NOX2 and NOX4 as a result of elevated levels of intracellular ROS levels. To study the effect of ROS on the expression of cytokines, the expression levels of cytokines were estimated by real-time PCR. TNF-a (Fig. 7a) was increased by 5.6 folds, IL-1b (Fig. 7b) increased by 1.8 folds (p ≤ 0.05), and IL-6 (Fig. 7c ) approximately 22 folds (p ≤ 0.01) in miR-17-inhibited cells as compared to Cy3 control. All three cytokines were found to be suppressed in the cells over-expressing miR-17, compared to controls (transfection control scramble miR-17). This indicated that elevated ROS levels led to increased cytokine expression through activated microglial cells. To check the effect of different stimuli on miR-17 levels, we treated HMC3 cells with BSA, HIV-1 Tat B and LPS. RT-PCR revealed no significant change in miR-17 levels (Fig. 7d) . This observation suggested that decreased expression of miR-17 affected downstream NOX2, NOX4, and ROS specifically in response to HIV-1 Tat C.
Discussion
HIV-1 infection extends into cognitive and motor dysfunctions collectively termed as HIV-associated neurological disorders. Neuroinflammation is either caused by direct infection of virus to the permissive neuronal cells (astrocytes or microglia) or by exposure of the cells to extracellularly secreted viral proteins like Tat, Vpr, Nef etc. ROS generated by phagocytic cells have primary function of destroying microbes. However, it has secondary role in modulating redox signaling pathways (Thannickal and Fanburg 2000) . ROS can lead to reversible chemical modifications in various transcription factors [NF-jB (nuclear factor kappa-light-chain-enhancer of activated B cells), redox-sensitive transcription family] affecting their functions and thus influencing the inflammatory responses of human microglial cells (Forman and Torres 2001) . ROS, produced during oxidative stress by activated microglial cells, may result in neuronal damage (Ghosh et al. 2014; Xing et al. 2014) . HIV infection modulates the miRNA expression pattern of the infected cells (Yeung et al. 2005) . miR-17 has been reported to target P300/CBP-associated factor, a Tat transcriptional cofactor required for HIV replication and establishing HIV latency (Triboulet et al. 2007) . miR-17 has been reported to be down-regulated by twofolds in HIV-infected CEMx174 cells (Hayes et al. 2011) .
Therefore, the levels of miR-17 were checked in HMC3 cells in response to HIV-1 Tat C protein. miR-17 was found to be down-regulated at early time points of HIV-1 Tat C protein exposure. Chronically activated microglial cells have been reported to secrete out neurotoxic factors, which could result in neuronal damage (Chao et al. 1992; Frank-Cannon et al. 2009 ). HIV Tat is known to activate microglial cells, leading to free radical stress (Turchan-Cholewo et al. 2009a) . Microglial cells express NOXs, which play a major role in ROS production pathway. miR-17 has one strong binding site in 3 0 UTR of NOX2 and three binding sites in 3 0 UTR of NOX4. The down-regulation of miR-17 has been reported in kidneys of diabetic nephropathy (DN) patients with increased NOX4 levels (Fu et al. 2010) .
HIV-1 Tat B exposed SH-SY5Y (neuronal cell line) and HN (primary human neurons) cells have shown the differential expression pattern of microRNAs. Tat B has been reported to induce miR-34a in SH-SY5Y cells, which targeted cAMP-response element binding protein, a neuroprotective protein . The increased expression of miR-1 has been reported in neurons exposed to HIV Tat protein. The miR-1 regulates Mef2A, further regulating the miR (379-410) cluster responsible for dendritogenesis (Fiore et al. 2009 ). HIV Tat exposure to neuronal cells results in the inhibition of miR-128a, which regulates the expression of pre-synaptic protein SNAP25 (Eletto et al. 2008) . We previously reported perturbation in microRNAs in brain microvascular endothelial cells and microglial cells upon Tat C exposure. miR-32 affected expression of inflammatory genes by targeting TRAF3 in microglial cells upon Tat C exposure (Mishra et al. 2012) . HIV-1 Tat C also induces miR-101 expression in brain microvascular endothelial cells, which targets VE-Cadherin and compromises blood-brain barrier integrity and permeability (Mishra and Singh 2013) . We observed down-regulation in miR-17 levels and consequent increase in expressions of NOX2, NOX4 in HMC3 cells exposed to HIV-1 Tat C. In addition, we studied the effect of increased NOX expression on ROS production. The ROS increased gradually within 24 h of HIV-1 Tat C exposure in HMC3 cells. The fluorimetry data and image analysis showed the maximum levels of ROS production at 24 h. The luciferase assay demonstrated the direct binding of miR-17 to the 3 0 UTR of NOX2 and NOX4 genes. The luciferase reporter assay performed in cotransfection experiments with miR-17 demonstrated the direct binding of miR-17 to 3 0 UTR of NOX2 and NOX4. The deletion mutant 3 0 UTR of NOX2 and NOX4 devoid of complementary binding sites for seed region of miR-17 could not show any reduction in luciferase activity. Reduction in luciferase activity was more in NOX4 than NOX2, which could be due to three perfect 7-mer binding sites of miR-17 in 3 0 UTR of NOX4 and presence of only one perfect 7-mer binding site in 3 0 UTR of NOX2. The ROS generation has been reported during various viral infections. HCV increases ROS production by inducing NOX4; which results in oxidative stress (Boudreau et al. 2009 ). HSV has been reported to produce ROS through NOX, which induces cytokine expression in microglial cells, resulting in neuronal damage (Hu et al. 2011) . To determine the specificity of post-transcriptional regulation of NOX2/ NOX4 genes by miR-17, we inhibited cellular miR-17 in HMC3 cells and observed the expression patterns of NOX2, NOX4 along with intracellular ROS production. Both the miR-17 inhibition and HIV-1 Tat C exposure resulted in increased expression of NOX2/NOX4 and elevated intracellular ROS generation. These findings have established that HIV-1 Tat C induces the intracellular ROS generation via down-regulation of miR-17 in microglial cells.
The miR-17 was over-expressed in HMC3 cells to further validate the specificity of miR-17-mediated regulation of NOX2 and NOX4. The over-expression of miR-17 resulted in significant reduction in expression of NOX2 and NOX4. Over-expression of scrambled miR-17 and non-specific miR-101 showed no significant changes in NOX2 and NOX4 levels, thus confirming the specificity of miR-17-mediated regulation of the NOX2 and NOX4. The over-expression of miR-17 in HMC3 cells did not result in the reduction in ROS production, compared to controls. This indicated the redundancy in ROS generation pathway. In addition to miR-17, other pathways may also contribute to ROS production. Therefore, miR-17 over-expression did not result in the reduction of ROS production above the controls. HIV-1 Tat C exposure induced the levels of ROS production in HMC3 cells but cells over-expressing miR-17 followed by HIV-1 Tat C exposure did not show any significant increase in ROS production. This may be due to the higher levels of miR-17 in HMC3 cells (exogenous over-expression), which may nullify the effect of HIV-1 Tat C protein.
Increased NOX expression induces ROS, and that results in the microglial activation by secretion of pro-inflammatory cytokines and chemokines (Li et al. 2009a; Qin et al. 2013; Chantong et al. 2014) . The elevated levels of NOX2 and NOX4 were due to reduced expression of miR-17, which resulted in increased ROS production. ROS activates microglial cells, which leads to the expression of various proinflammatory cytokines. TNF-a, IL-1b, and IL-6 were found to be raised by several folds in HMC3 cells transfected with miR-17 inhibitor. Reduced levels of miR-17 resulted in increase in ROS, which in turn activated microglia and led to increased expression of cytokines. These cytokines were found to be suppressed in cells over-expressing miR-17, which demonstrated the miR-17-mediated regulation of ROS production and other downstream molecules by targeting NOX2 and NOX4. HIV Tat protein has been reported to induce the expression of cytokines and chemokines (Chen et al. 1997; Sheng et al. 2000; Williams et al. 2010; Jin et al. 2012 ) through NOX (Turchan-Cholewo et al. 2009b) . The roles of cellular microRNAs have been reported in different disease models. miR-9 has been reported to target monocyte chemotactic protein-induced protein 1 during microglial activation in neurodegenerative diseases (Yao et al. 2014) . miR-124 has been reported to target C/EBPa (CCAAT/enhancer-binding protein-a) in monocyte-lineage cells, deactivating macrophages by polarizing them from M1 to M2 and promoting microglial differentiation (Ponomarev et al. 2011) . The role of miR-200b in microglial cells has been reported in neuroinflammation by modulating JNK (cJun N-terminal Kinase) and mitogen-activated kinases (Jadhav et al. 2014) . miR-21 has been reported to regulate Fas ligand in hypoxia-mediated microglial activation, which leads to microglia-mediated neuronal apoptosis (Zhang et al. 2012) . We have demonstrated that the modulation of miR-17 by HIV-1 Tat C in microglial cells results in microglial activation via NOX2, NOX4, and ROS.
The treatments of HMC3 cells with BSA, HIV-1 Tat B, and LPS did not lead to any significant changes in the expression of miR-17 levels. Thus, HIV-1 Tat C specifically activated the microglial cells by targeting This study demonstrated a novel microRNA-mediated mechanism of ROS generation in human microglial cells in response to HIV Tat C protein, which may lead to neuroinflammation and neurodegeneration among HIVpositive patients. This study has been carried out on human microglial cell line (HMC3). Cell lines are based on oncogenic transformations and show drifting patterns of cell surface expression. Therefore, further studies are required on primary cells and/or animal models in light of the current observations of this study. All experiments were conducted in compliance with the ARRIVE guidelines.
